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Introduction 
Predictors of mortality after aortic valve 
replacement (AVR) varies widely among the 
published series [1,2]. This variation is attributed 
mainly to different population characteristics, 
valve pathology, and different surgical outcomes 
in various centers.  
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Abstract 
Background: Several risk factors, including emergency surgery, predicted early 
mortality after aortic valve replacement (AVR).  Euroscore II is used to predict the 
mortality after cardiac operations. We aimed to review our experience in AVR and 
determine the early mortality predictors  
Methods: We collected the data of 200 rheumatic patients who had standard AVR 
in two centers. Median sternotomy and cardiopulmonary bypass were used in all 
patients. Transcatheter and minimally invasive aortic valve replacement patients 
were excluded. We used 15 types of aortic valve prostheses, either mechanical or 
biological. Follow-up echocardiography was done in the intensive care unit, on 
discharge, and one month after discharge.     
Results: 128 patients (64%) had mechanical AVR, and 130 patients (65%) were 
males. The mean age was 48.2 ± 19 years, and body mass index was 1.8 ± 0.2 
Kg/m2. The mean preoperative ejection fraction was 54 ± 9.4 %, end-diastolic 
dimension was 5.3 ± 0.8 cm, and end-systolic dimension was 3.5 ± 0.9 cm. Nine 
patients (4.5%) died in the early postoperative period (6 months). Euroscore II was 
the only factor significantly associated with early mortality (P value= 0.031).  The 
mean Euroscore II was 1.3 ± 0.9 and 10.1 ± 10.7 for survivors and non-survivors, 
respectively.   
Conclusion: Euroscore II score was significantly associated with early mortality 
after aortic valve replacement in rheumatic patients and can be used for risk 
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Several risk stratification scores (Euroscore I, 
Euroscore II, Society of thoracic surgery (STS) 
score, and the Australian model) were compared 
to predict the operative mortality after isolated 
AVR [3]. The Euroscore I had a poor calibration 
value and overestimated the mortality; however; 
the other scores correlated well with the 
outcome, and the highest accuracy was 
reported with STS score [3-5]. Other studies 
found that the Euroscore II was as effective as 
the STS risk score in predicting operative 
mortality [6]. Additionally, the Euroscore II has 
the additional benefit of having greater 
flexibility in terms of its applicability to a 
variety of cardiac surgeries.   Most risk score 
systems have benefits and drawbacks and 
are meant to help rather than to govern clinical 
decision making. Several authors believe that 
no clinical decision should be made solely based 
on a calculated risk score, and every risk score 
system should be validated on different patients’ 
subset in different areas [6]. 
The objectives of this study were to report our 
experience in AVR and to determine the 
predictors of early mortality.   
Patients and Methods: 
Design and Patients:  
This is a retrospective cohort study including 
200 patients who had AVR for rheumatic aortic 
valve disease during the period from January 2011 
to December 2016. Patients with other valve 
pathology and those who had minimal invasive or 
transcatheter AVR were excluded from the study. 
The Ethical Committee and Research Center 
approved the study, and the patients’ consent for 
data retention and utilization for research purpose 
was taken during the procedure consent.  
Data collection:  
We collected the data from the medical charts, 
including the preoperative patients’ 
characteristics, comorbidities, echocardiographic 
data, and postoperative complications. Patients 
enrolled in this study were referred from the 
Cardiology Department after a physical 
examination, chest x-ray (CXR), echocardiography, 
and routine preoperative investigations were 
done. Cardiac catheterization was performed for 
cases older than 40 years and those with clinically 
significant chest pain. The decision for surgery was 
decided after multidisciplinary discussion with the 
heart team. Indication of surgery was based upon 
echocardiography, cardiac catheterization, and 
the severity of patient symptoms. Informed 
consent was done for the cases scheduled for 
surgical AVR after explaining the nature of the 
disease, options of treatment, type of the 
prostheses, and risk factors.  
Operative procedure: 
General anesthesia was induced after 
insertion of the venous and arterial lines. We 
routinely use Trans-esophageal echocardiography 
(TEE) to confirm/re-evaluate the aortic valve and 
other valves and assure good deairing. AVR was 
performed through a median sternotomy. 
Pericardial stay sutures were placed, heparin (400 
IU/kg) was infused, and aortic cannulation 
followed by two-stage venous cannulation and 
retrograde cardioplegia cannula were inserted. 
Target active clotting time (ACT) was 400 seconds 
to initiate cardiopulmonary bypass (CPB), 
antegrade blood cardioplegia, either cold or 
warm, was used according to surgeon 
preferences. This was followed by retrograde 
cardioplegia if needed, plus intermittent doses of 
retrograde with occasional doses directly down 
the coronary ostia. Left ventricle (LV) vent was 
inserted through the right superior pulmonary 
vein. The aortotomy is performed as small 
transverse or oblique incision one cm above the 
right coronary artery (RCA) then extended laterally 
towards the left coronary artery (LCA) ostium, 
then medially in an oblique fashion towards the 
middle of the non-coronary sinus. The valve was 
inspected then resected along the annulus. We 
debrided the calcium, then sized the valve and 
placed horizontal mattress sutures along the 
annulus (using 2-0 braided pledged). The sutures 
were passed through the valve ring; then the valve 
was seated.  
Postoperative care: 
The patient was kept in the intensive care unit 
(ICU) ventilated until he/she became fully 
conscious with stable hemodynamics and being 
able to protect the airways when extubated.  
Anticoagulation was given permanently in 
mechanical valves and for three months in 
biological valves. INR was kept between 2-2.5. 
Follow-up echocardiography was done in ICU, on 
discharge, and one month after discharge. The 
patient was discharged home, and the instructions 
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regarding the anticoagulation, fever, sternal 
protection, and further follow-up were given.  
Study outcome: 
The outcome of this study was the early 
mortality defined as mortality occurring within 6 
months of the operation, whether during 
hospitalization or after discharge. 
Statistical analysis: 
The data were analyzed using SPSS 20 (IBM 
Corp, Chicago, IL, USA). Continuous variables were 
expressed as mean ± standard deviation, median, 
and interquartile range. Categorical variables 
were expressed as number and percentage. 
Student t-test or Mann-Whitney test were used to 
compare continuous variables and Chi-square, or 
Fisher exact tests were used to compare 
categorical variables. A p-value of less than 0.05 
was considered significant. 
Table 1: Baseline characteristics of the patients. 
Variable Total Patients (n=200) 
Age (Years) 
Mean ± SD 
Median (IQR) 
48.2 ± 19 
50 (33- 63) 






Mean ± SD 
Median (IQR) 
28.7 ± 6.8 
28.4 (23.6-32.8) 
BSA (m2) 
Mean ± SD 
Median (IQR) 
1.8 ± 0.2 
1.8 (1.6- 2) 
ES II 
Mean ± SD 
Median (IQR) 
1.6 ± 2.3 
0.9 (0.6- 1.7) 
SD: Standard deviation; BMI: Body mass index; 
BSA: Body surface area; ES: Euroscore 
Results 
Preoperative data: 
Our study included 200 patients, 128 had 
mechanical AVR (64%), and 130 were males (65%). 
Fifteen different prostheses were used, including 
both mechanical and bioprostheses. Valve sizes 
ranged between 19 and 27, and size 19 was used 
in 12 patients (24%). The mean age was 48.2 ± 19 
years, and body mass index (BMI) was 1.8 ± 0.2 
Kg/m2. Aortic stenosis was the main pathology in 
66.5% of the patients, and 33.5% had regurge or 
mixed pathologies. The mean preoperative 
Euroscore II for all patients was 1.8 ± 0.2. Isolated 
aortic valve replacement was performed in 130 
patients (65%), 29 patients (14.5%) had 
concomitant coronary artery bypass grafting, 26 
patients (13%) had double valve replacement, and 
15 patients (7.5%) had triple valve surgery.  Bentall 
procedure was performed in nine cases (4.5%).  
29 patients (14.5%) had reoperation. Table 1 
showed the baseline characteristics of the 
patients. The mean preoperative ejection fraction 
(EF) was 54 ± 9.4%, the end-diastolic dimension 
(EDD) was 5.3 ± 0.8 cm, and the end-systolic 
dimension (ESD) was 3.5 ± .9 cm.  (Table 2)  
Table 2: Baseline Echo characteristics of the patients 
Variable Total Patients (n=200) 
EF (%) 
Mean ± SD 
Median (IQR) 
54 ± 9.4 
55 (50- 60) 
EDD (cm) 
Mean ± SD 
Median (IQR) 
5.3 ± .8 
5.3(4.7- 6) 
ESD (cm) 
Mean ± SD 
Median (IQR) 
3.5 ± .9 
3.4 (2.9- 4.1) 
PAPs (mmHg) 
Mean ± SD 
Median (IQR) 
37.1 ± 12.9 
30 (30- 45) 
LVPWd (cm) 
Mean ± SD 
Median (IQR 
1.2 ± .21 
1.1 (.9- 1.2) 
AV peak gradient max (mmHg) 
Mean ± SD 
Median (IQR) 
76.8 ± 46.8 
78.7 (34.4- 106.9) 
AV mean gradient (mmHg) 
Mean ± SD 
Median (IQR) 
48.6 ± 22.6 
48.7 (33.3- 64.2) 
EF: Ejection fraction; EDD: End diastolic 
diameter; ESD: End systolic diameter; PAPs: 
systolic pulmonary artery pressure; LVPWD: 
left ventricular posterior wall diameter; AV: 
aortic valve 
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Early mortality: 
There were nine deaths (4.5%) within the first 
six months after the operation; six were females 
and three males. Mortality occurred in five 
patients with mechanical valves, and four with 
biological valves.   Timing of mortality is shown in 
Table 3. By univariable analysis, Euroscore II was 
significantly associated with early mortality (P 
value= 0.031).  The mean Euroscore II was 1.3 ± 0.9 
and 10.1 ± 10.7 for survivors and non-survivors, 
respectively (Table 4). 
   Postoperative  complications were new-onset 
AF in 28 (14%), stroke in 17 (8.5%), complete 
heart block (CHB) in seven (3.5%), bleeding in 18 
(9%), prolonged ventilation in 14 (7%), prolonged 
ICU stay in 26 (13%), sepsis in 12 (6%) and 
multiorgan failure in 10 (5%) patients. 
Table 3: Timing of mortality 
Variable Total Patients (n=200) 
Mortality  9 (4.5%) 
Mortality < 30 days 4 (2%) 
Mortality > 30 days 5 (2.5%) 
Discussion 
We retrospectively studied 200 patients who 
had AVR for rheumatic valve disease. The data 
were collected from two tertiary centers in two 
years. We reported a 4.5% mortality rate, which is 
consistent with international standards. The 
causes of death were end-organ failures with the 
hepato-renal syndrome and sepsis. The 
univariable analysis showed that Euroscore II was 
the only factor significantly associated with 
mortality.  
Risk factors of mortality after AVR vary widely 
between different centers. Previously reported 
risk factors included old age, congestive heart 
failure, myocardial infarction, low EF, left 
ventricular dysfunction, emergency operation, 
type and size of the prosthesis,  concomitant 
procedure especially coronary artery bypass 
grafting (CABG) and mitral valve replacement 
(MVR), long cross-clamp time, long  
cardiopulmonary bypass time, need of intra-aortic 
balloon pump, low cardiac output syndrome , and 
postoperative complications [1,7]  
Swinkels and associates developed the AVR 
score as a simple risk score to predict 30-day 
mortality [8]. Euroscore and STS score, though 
more complex, they can provide a first quick-look 
impression of 30-day mortality after AVR. Hannan 
and associates reported a 3.33% mortality rate 
after isolated aortic valve replacement and 2.63% 
in patients who had mechanical valve prosthesis 
[9]. Mortality was higher in heterograft (4.22%) 
than homograft (3.28%) and with concomitant 
CABG (7.12%) [10]. Sharabiani and associates 
found the Euroscore II >5 to be a significant 
predictor of in-hospital/30-day mortality [11,12].  
There are four risk scores (Euroscore, 
Euroscore II, STS score, and Australian AVR risk 
score) to predict mortality after cardiac surgery. 
Euroscore includes patient-related factors, 
cardiac-related factors, and operation-related 
factors [13,14]. The predictability of the scores 
could vary between different regions because of 
the nature of the disease and patients’ 
characteristics. In our region, rheumatic heart 
disease is the primary cause of aortic valve 
disease, in contrary to the age-related aortic 
calcification in the developed countries. 
Additionally, the prevalence of comorbidities in 
our regions is different from that of the developed 
world. Euroscore did not consider the effect of 
liver disease on the outcome, which has a high 
prevalence in the Middle East.    
Euroscore II had better predictive 
discrimination for operative mortality than 
Euroscore I and is comparable to the STS risk 
score [3]. This may be due to the inclusive nature 
of Euroscore II for many procedures that make it 
more flexible than the STS score for complex 
procedures. Euroscore II should be considered for 
calculating the risk score for complex cardiac 
surgical patients [3,13].  
Several risk factors affect the outcome of 
aortic surgery and are not included in the risk 
score systems such as the type of the prosthesis 
[14], and several intraoperative factors have a 
significant effect on the postoperative course 
[15]. Comprehensive echocardiographic details 
are not included in most cardiac risk scoring 
systems, and no echocardiographic finding 
predicted the mortality in our series. It is 
essential to validate the scoring system in each 
region and study the region-specific risk factors 
that can affect the outcomes. In addition to the 
cardiac surgery-specific risk score systems, other 
non-cardiac
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Table 4: Characteristics of the survivor and non-survivor 
Variable Survivor (n=191) Nonsurvivor (n=9) P-value 
Age (Years) 
Mean ± SD 
Median (IQR) 
47.6 ± 19.2 
50 (32.2-63) 
60 ± 9.3 
54 (53-70) 
0.143 









Mean ± SD 
Median (IQR) 
28.6 ± 6.9 
28.3 (23.5 - 32.8) 




Mean ± SD 
Median (IQR) 
1.8 ± 0.2 
1.8 (1.6 - 2) 




Mean ± SD 
Median (IQR) 
1.3 ± 0.9 
0.9 (0.6 – 1.6) 




Mean ± SD 
Median (IQR) 
53.8 ± 9.3 
55 (50 – 60) 




Mean ± SD 
Median (IQR) 
5.3 ± 0.8 
5.3 (4.7 – 6) 




Mean ± SD 
Median (IQR) 
3.6 ± 0.9 
3.4 (2.9 – 4.1) 




Mean ± SD 
Median (IQR) 
36.9 ± 13.2 
30 (30 – 45) 




Mean ± SD 
Median (IQR) 
1.1 ± 0.2 
1.1 (0.9 – 1.2) 




Mean ± SD 
Median (IQR) 
1.15 ± 0.2 
1.2 (1 – 1.3) 




Mean ± SD 
Median (IQR) 
1 ± 0.1 
1.1 (0.9 – 1.2) 
1.2 ± 0.2 
1.3 (0.9-1.4) 
0.145 
LV mass (g) 
Mean ± SD 
Median (IQR) 
260.5 ± 93.7 
235.7 (193 – 313.8) 
200.1 ± 56.3 
191.9 (150.5-257.8) 
0.166 
Calculated LV mass (g) 
Mean ± SD 
Median (IQR) 
257.6 ± 92.4 
230.1 (188.4 – 310.9) 
196.7 ± 53.6 
188.5 (149.7-251.8) 
0.160 
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Table 4 (Continued) 
Variable Survivor (n=191) Nonsurvivor (n=9) P-value 
LV mass indexed (g/m2) 
Mean ± SD 
Median (IQR) 
138.3 ± 50.5 
130 (104.4 – 169.6) 
108.5 ± 34.1 
99.2 (83.1-143.3) 
0.170 
AV peak gradient  max (mmHg) 
Mean ± SD 
Median (IQR) 
77± 47.3 




AV mean gradient (mmHg) 
Mean ± SD 
Median (IQR) 
49.1± 22.7 




SD: standard deviation; BMI: Body mass index; BSA: Body surface area; EF: ejection fraction; ES: 
Euroscore; EDD: End diastolic diameter; ESD: End systolic diameter; PAPs: systolic pulmonary artery 
pressure; IVSD= interventricular septal diameter; LVPWD: left ventricular posterior wall diameter; AV: 
aortic valve
score systems were used to predict the outcome 
after cardiac surgery such as SOFA and APACHE 
scores [16]. 
Limitations: 
This is a retrospective study in two centers with all 
the inherent defects of retrospective studies. 
Small patients number is another limitation. We 
used univariable analysis to identify risk factors for 
early mortality and the low events number 
precluded further multivariable analysis.  
Conclusion 
Euroscore II score was significantly associated 
with early mortality after aortic valve replacement 
in rheumatic patients and can be used for risk 
stratification in those patients. 
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